These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 16469003)

  • 21. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Watchful waiting in benign prostatic hyperplasia.
    Wiygul J; Babayan RK
    Curr Opin Urol; 2009 Jan; 19(1):3-6. PubMed ID: 19057209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The natural history of benign prostatic hyperplasia.
    Fitzpatrick JM
    BJU Int; 2006 Apr; 97 Suppl 2():3-6; discussion 21-2. PubMed ID: 16507045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Drugs for prostatic adenoma].
    Portet-Brunet L
    Soins; 1995 Oct; (599):69-70. PubMed ID: 8701357
    [No Abstract]   [Full Text] [Related]  

  • 25. [Medical therapy of benign prostatic hyperplasia].
    Altarac S
    Lijec Vjesn; 2005; 127(11-12):316-23. PubMed ID: 16583940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alpha-adrenergic receptor antagonists in older patients with benign prostatic hyperplasia: issues and potential complications.
    Fine SR; Ginsberg P
    J Am Osteopath Assoc; 2008 Jul; 108(7):333-7. PubMed ID: 18648026
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of alpha1-adrenoceptors on prostate cancer growth.
    Stamatiou K; Skolarikos A; Sofras F
    Urology; 2008 Apr; 71(4):756-7. PubMed ID: 18291511
    [No Abstract]   [Full Text] [Related]  

  • 28. [The experience in postoperative administration of alpha-adrenoblockers].
    Miller AM
    Urologiia; 2007; (5):55-8. PubMed ID: 18254227
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study.
    Nishino Y; Masue T; Miwa K; Takahashi Y; Ishihara S; Deguchi T
    BJU Int; 2006 Apr; 97(4):747-51, discussion 751. PubMed ID: 16536766
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
    Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
    BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: Alpha-blockade in the treatment of symptomatic benign prostatic hyperplasia.
    Hansen BJ
    J Urol; 1996 Jul; 156(1):184-5. PubMed ID: 8648797
    [No Abstract]   [Full Text] [Related]  

  • 32. [Phenoxybenzamine in prostatic pathology. 300 cases (author's transl)].
    Lardennois B; El Khansa A; Amory JP; Coulon JM; Lemaire P
    J Urol (Paris); 1981; 87(4):243-8. PubMed ID: 6167646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both?
    Carson CC
    BJU Int; 2006 Apr; 97 Suppl 2():39-43; discussion 44-5. PubMed ID: 16507053
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE.
    Roehrborn CG
    BJU Int; 2008 Mar; 101 Suppl 3():17-21. PubMed ID: 18307681
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alfuzosin for benign prostatic hypertrophy.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Oct; 338(8772):947. PubMed ID: 1717801
    [No Abstract]   [Full Text] [Related]  

  • 37. Alfuzosin for benign prostatic hypertrophy.
    Chapple CR
    Lancet; 1991 Jul; 338(8760):182. PubMed ID: 1712882
    [No Abstract]   [Full Text] [Related]  

  • 38. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new?
    Morgia G
    Eur Urol; 2011 Mar; 59(3):353-5; discussion 355. PubMed ID: 21130562
    [No Abstract]   [Full Text] [Related]  

  • 39. Medical management of lower urinary tract symptoms in men: current treatment and future approaches.
    Patel AK; Chapple CR
    Nat Clin Pract Urol; 2008 Apr; 5(4):211-9. PubMed ID: 18301417
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: the cardiovascular system.
    Barendrecht MM; Koopmans RP; de la Rosette JJ; Michel MC
    BJU Int; 2005 Jun; 95 Suppl 4():19-28. PubMed ID: 15871732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.